Zydus Lifesciences Settles Patent Dispute with Astellas

Zydus Lifesciences Limited has finalized a settlement agreement with Astellas Pharma Inc., ending a long-standing patent dispute over the blockbuster drug Myrbetriq (Mirabegron), used to treat overactive bladder.

Key Highlights:

• Settlement Terms: Zydus will pay USD 120 million upfront to Astellas, along with licensing fees until September 2027.
• Litigation Closure: The agreement concludes all ongoing U.S. patent litigations between the two companies.
• Market Continuity: Zydus retains the right to market its generic version of Mirabegron in the United States.
• Strategic Impact: This settlement strengthens Zydus’ foothold in the U.S. generics market, particularly in specialty therapies.
• Industry Context: The deal follows similar settlements by other Indian pharma firms, highlighting the growing competitiveness in the global generics space.

This resolution not only secures Zydus’ position in the lucrative U.S. market but also reflects the company’s strategic approach to balancing litigation risks with commercial opportunities.

Sources: ScanX News, CNBCTV18